Latest ARCH VENTURE CORP Stock Portfolio

$266Million– No. of Holdings #9

ARCH VENTURE CORP Performance:

2024 Q2: -8.1%YTD: -8.61%2023: -8.31%

Performance for 2024 Q2 is -8.1%, and YTD is -8.61%, and 2023 is -8.31%.

About ARCH VENTURE CORP and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, ARCH Venture Management, LLC reported an equity portfolio of $266 Millions as of 30 Jun, 2024.

The top stock holdings of ARCH Venture Management, LLC are BEAM, , ERAS. The fund has invested 47.9% of it's portfolio in BEAM THERAPEUTICS INC. and 32.6% of portfolio in RAPPORT THERAPEUTICS, INC.

The fund managers got completely rid off DENALI THERAPEUTICS, INC. (DNLI) and SINGULAR GENOMICS SYSTEMS, INC. (OMIC) stocks. ARCH Venture Management, LLC opened new stock positions in BEAM THERAPEUTICS INC. (BEAM), RAPPORT THERAPEUTICS, INC. and SINGULAR GENOMICS SYSTEMS, INC. (OMIC).

ARCH VENTURE CORP Equity Portfolio Value

Last Reported on: 14 Aug, 2024

ARCH VENTURE CORP Annual Return Estimates Vs S&P 500

Our best estimate is that ARCH Venture Management, LLC made a return of -8.1% in the last quarter. In trailing 12 months, it's portfolio return was -16.09%.

New Buys

Ticker	$ Bought
beam therapeutics inc.	127,530,000
rapport therapeutics, inc.	86,730,400
singular genomics systems, inc.	1,070,020

New stocks bought by ARCH VENTURE CORP

Additions

No additions were made to existing positions by ARCH VENTURE CORP

Reductions

None of the existing positions were reduced by ARCH VENTURE CORP

Sold off

Ticker	$ Sold
denali therapeutics, inc.	-7,823,230
singular genomics systems, inc.	-1,953,410

ARCH VENTURE CORP got rid off the above stocks

Sector Distribution

ARCH Venture Management, LLC has about 65.1% of it's holdings in Healthcare sector.

Sector	%
Healthcare	65.1
Others	34.9

Market Cap. Distribution

ARCH Venture Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	47.9
UNALLOCATED	34.9
SMALL-CAP	13.5
MICRO-CAP	2.7

Stocks belong to which Index?

About 61.4% of the stocks held by ARCH Venture Management, LLC either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	61.4
Others	38.6

Top 5 Winners (%)		%
OMIC	singular genomics systems, inc.	2012.5 %
ERAS	erasca, inc.	14.6 %

Top 5 Winners ($)		$
ERAS	erasca, inc.	3.3 M
OMIC	singular genomics systems, inc.	1.0 M

Top 5 Losers (%)		%
VERV	verve therapeutics, inc.	-63.3 %
GOSS	gossamer bio, inc.	-23.6 %
UBX	unity biotechnology, inc.	-17.7 %
BEAM	beam therapeutics inc.	-0.8 %

Top 5 Losers ($)		$
VERV	verve therapeutics, inc.	-16.9 M
GOSS	gossamer bio, inc.	-2.2 M
BEAM	beam therapeutics inc.	-1.1 M
UBX	unity biotechnology, inc.	-0.3 M

ARCH VENTURE CORP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of ARCH VENTURE CORP

ARCH Venture Management, LLC has 9 stocks in it's portfolio. VERV proved to be the most loss making stock for the portfolio. ERAS was the most profitable stock for ARCH Venture Management, LLC last quarter.

Last Reported on: 14 Aug, 2024

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
BEAM	beam therapeutics inc.	47.94	5,443,040	127,530,000	new

DNLI	denali therapeutics, inc.	0.00	0.00	0.00	sold off	-100

ERAS	erasca, inc.	9.81	11,055,600	26,091,100	unchanged	0.00

GOSS	gossamer bio, inc.	2.73	8,055,920	7,257,580	unchanged	0.00

OMIC	singular genomics systems, inc.	0.40	126,630	1,070,020	new

OMIC	singular genomics systems, inc.	0.00	0.00	0.00	sold off	-100

PBAX	cero therapeutics holdings, inc.	0.16	1,444,300	431,845	unchanged	0.00

UBX	unity biotechnology, inc.	0.51	1,004,820	1,356,500	unchanged	0.00

VERV	verve therapeutics, inc.	3.68	2,008,810	9,802,990	unchanged	0.00

	rapport therapeutics, inc.	32.60	3,728,740	86,730,400	new

	q32 bio inc.	2.16	320,482	5,752,650	unchanged	0.00